Protecting challenges to monopolies
By: David Gonen, Bureau of Competition | Feb 28, 2017 9:11AM
Blog Posts Tagged with Prescription Drugs
Monitors: Expert eyes and ears in Commission orders
By: Susan Huber, Bureau of Competition | Jul 14, 2015 11:59AM
The ability to appoint a monitor is an important tool in building a successful merger remedy. The boilerplate-style language FTC uses in merger orders when appointing a monitor belies the unique and varied roles that monitors play in assuring that the order maintains or restores competition. Here’s some background and insight into some of the ways the FTC uses monitors.
Continue Reading Monitors: Expert eyes and ears in Commission orders
Double dog dare: Read FTC staff’s new report on pet medications competition
By: Tara Isa Koslov and Stephanie Wilkinson, Office of Policy Planning | May 27, 2015 6:14PM
FTC staff has doggedly tracked down information about competition in the pet medications industry for the past several years. Why? Because it’s a large and growing consumer market. With 65 percent of American households owning a pet, and retail sales of prescription pet medications expected to top $10 billion by 2018, it is clearly a market where competition could benefit consumers. Most consumers pay for pet meds out-of-pocket and do not have pet health insurance that covers these expenses.
Continue Reading Double dog dare: Read FTC staff’s new report on pet medications competition
From the antitrust mailbag: What can the FTC do about prescription drug price spikes?
By: Alan Friedman, Bureau of Competition | May 18, 2015 12:31PM
Consumers frequently contact the Bureau of Competition to alert us that the cost of a prescription drug suddenly spiked up, and ask if the FTC can take antitrust action to bring the price back down. The answer in a nutshell is that it depends on the reason for the price change.
Generic drug firms deter entry by lowering price
By: Steven Tenn and Brett Wendling, Bureau of Economics | Jun 13, 2014 3:51PM
In a recently published article, we discuss our finding that generic drug companies successfully use low-pricing strategies to discourage entry by new competitors in certain circumstances.
Continue Reading Generic drug firms deter entry by lowering price
The FTC’s biologics workshop is underway!
By: Neal Hannan, Office of Policy Planning | Feb 3, 2014 4:29PM
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines.
You can view a live webcast of the workshop on the FTC’s website, or follow live tweets all day at #FTCFOB.
By: Neal Hannan, Office of Policy Planning | Feb 3, 2014 2:13PM
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
Competition to reduce the costs of biologic medicines
By: Elizabeth Jex, Office of Policy Planning | Dec 9, 2013 1:31PM
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin, used to treat breast cancer, can cost more than $50,000 a year; Remicade, which treats rheumatoid arthritis, more than $10,000 a year.
Continue Reading Competition to reduce the costs of biologic medicines
